111 West Lemon Avenue
To create its XmAb antibody engineering platform, Xencor precisely alters the Fc domain — the stem of the antibody structure — to significantly enhance natural functions and performance. In some cases, these modifications create entirely new therapeutic mechanisms of action.
Xencor’s broad portfolio of optimized Fc domains can plug-and-play into nearly any antibody. XmAb Fc domains provide enhanced performance in 11 proprietary and partnered therapeutic antibody programs in clinical development for the treatment of autoimmune disorders, cancer, asthma and allergic diseases.
The plug-and-play nature of Xencor’s XmAb technology enables the rapid creation of more powerful, more effective antibodies by simply changing a few amino acids in the Fc domain to the amino acids identified by our structure-based design. Typically two amino acids are changed to create the XmAb Fc domain and dramatically enhance the biological function of the antibody. Xencor’s growing pipeline is based on this plug-and-play approach to creating differentiated antibody drug candidates.
Xencor extends the use of the XmAb technology through licenses of these high-performance Fc domains to partners interested in therapeutic targets outside of Xencor’s areas of focus. Currently, partners are advancing seven programs in clinical trials and numerous pre-clinical programs that use XmAb Fc domains for bispecific structure, higher cytotoxicity, longer half-life or improved stability.
209 articles with Xencor
Dr. Grunstein brings more than 15 years of expertise in partnering, acquisitions and licensing in the biopharmaceutical industry and will lead strategic partnering to enhance the development of Xencor’s pipeline of drug candidates.
Xencor, Inc. reported financial results for the first quarter ended March 31, 2019 and provided a review of recent business and clinical highlights.
Xencor, Inc. announced that company management will present at two upcoming conferences
Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors
XmAb23104, a PD-1 x ICOS bispecific antibody, is the sixth XmAb® antibody engineered with Xencor’s bispecific Fc domain to enter clinical development
It will release first quarter 2019 financial results after the market closes on Thursday, May 9, 2019.
Xencor, Inc. announced the U.S. Food and Drug Administration has lifted the partial clinical hold that was placed on the Phase 1 study of XmAb14045, a CD123 x CD3 bispecific antibody molecule being evaluated in patients with relapsed or refractory acute myeloid leukemia and other CD123-expressing hematologic malignancies.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a research and license agreement in which Astellas Pharma Inc. will access Xencor’s bispecific technology to advance a novel bispecific antibody program in oncology
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in two upcoming conferences:
Xencor, Inc. announced the closing of its research collaboration and license agreement with Genentech, a member of the Roche Group, following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976.
Initial Data from Phase 1 Study of XmAb®14045 Presented at ASH 2018; Multiple Complete Remissions Achieved in Advanced AML Patient Population; Study on Partial Clinical Hold Pending Resolution with FDA
Xencor, Inc. announced that the U.S. Food and Drug Administration has placed a partial clinical hold on its Phase 1 study of XmAb14045, a CD123 x CD3 bispecific antibody molecule being evaluated in patients with relapsed or refractory acute myeloid leukemia and other CD123-expressing hematologic malignancies.
The patients were part of a trial assessing Xencor's mAb14045, a CD123 x CD3 bispecific antibody molecule being evaluated in patients with relapsed or refractory acute myeloid leukemia.
Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release fourth quarter and full year 2018 financial results after the market closes on Monday, February 25, 2019.
Xencor, Inc. announced that company management will participate in fireside chats at two upcoming conferences:
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, today announced it has entered into a research and license agreement with Genentech
Genentech, a Roche company, is flexing its litigation muscle this week. The South San Francisco-based company has filed 18 lawsuits over the past few weeks to block competitors from selling a generic version of a treatment for idiopathic pulmonary fibrosis, a fatal lung-scarring disease.
Initial data from the ongoing Phase 1 study in patients with B-cell malignancies expected in 2019
Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
Xencor, Inc. today announced initial data from its ongoing Phase 1 dose-escalation study of XmAb®14045, a CD123 x CD3 bispecific antibody, in patients with relapsed/refractory acute myeloid leukemia (AML).
Xencor, Inc. today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 10:30 a.m. ET in New York, NY.
Dr. Feigal is currently a partner at NDA Partners, a strategy consulting firm, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology.